<div>
    <div class="column-sub" style="width:1%">
        &nbsp;
    </div>

    <div class="column-prime" style="width:75%">
        <br/>
        <div class="section far2x">

            <b>Welcome to the BV-BRC SARS-CoV-2 Real-time Tracking and Early Warning System for Variants and Lineages of Concern (VoCs/LoCs)</b>
            <p>
                VoCs/LoCs are sequence variants or lineages that may significantly affect vaccine efficacy, transmissibility, disease outcomes,
                or other factors critical to gaining control of COVID-19 disease.
                The VoC list is based on variants compiled by the <a href="https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.html" target=_blank>CDC</a>.
                The VoI list is based on work by the NIAID SAVE Early Detection Working Group [public hyperlink]. <br/>
                The <b>SARS-CoV-2 Variants and Lineages of Concern</b> resource
                <ul>
                    <li>Identifies and tracks emerging variants and lineages through daily processing of publicly available SARS-CoV-2 sequences</li>
                    <li>Performs risk assessment on the variants to identify candidate VoCs/LoCs by leveraging a growing knowledgebase of
                        sequence features, including protein domains, functional regions, and immune epitopes</li>
                    <li>Provides detailed information about each VoC/LoC</li>
                    <li>Provides their sequence prevalence in various countries and regions over time using interactive dashboards and charts</li>
                    <li>Provides integrated view of the VoCs/LoCs and important sequence features using genome browsers, protein structure viewers, and phylogenetic trees</li>
                </ul>
                <br/>
                For more information, please see <a href="/patric/pdf/sars-cov-2-loc-tutorial.pdf" target=_blank>The BV-BRC Real-time Tracking and Early Warning System for SARS-CoV-2 Variants and Lineages of Concern (VoCs/LoCs) Tutorial</a>.
            </p>
        </div>
        <div class="section close2x">
            <h3 class="close2x section-title"><span class="wrap">Lineages of Concern</span></h3>
            <table class="p3basic striped">
                <thead>
                    <tr>
                        <th>LoC name</th>
                        <th>PANGO lineage</th>
                        <th>NextStrain lineage</th>
                        <th>WHO name</th>
                        <th>Other synonyms</th>
                        <th>Emergence date</th>
                        <th>Emergence location</th>
                        <th>Representative strain</th>
                        <th>AA substitutions in spike protein</th>
                        <th>Impact</th>
                    </tr>
                </thead>
                <tbody>
                    <tr><!-- B.1.1.7 -->
                        <td><a href="/view/VariantLineage/#view_tab=lineage&loc=B.1.1.7">B.1.1.7</a></td>
                        <td><a href="https://cov-lineages.org/global_report_B.1.1.7.html" target=_blank>B.1.1.7</a></td>
                        <td>20I(Alpha, V1)</td>
                        <td>Alpha</td>
                        <td>VOC 202012/01, UK variant</td>
                        <td>September 2020</td>
                        <td>United Kingdom</td>
                        <td>
                            <a href="https://www.viprbrc.org/brc/viprStrainDetails.spg?ncbiAccession=MW642026&decorator=corona_ncov&context=1625086072003" target=_blank>SARS-CoV-2/human/USA/OH-UHTL-43/2021</a>
                        </td>
                        <td>H69-**, V70-**, N501Y**, A570D, D614G**, P681H, T716I, S982A, D1118H</td>
                        <td>Increased transmissibility; S gene target failure (SGTF);
                            <a href="https://www.nature.com/articles/s41586-021-03426-1)" target=_blank>increased severity</a>;
                            <a href="https://www.fda.gov/media/145802/download" target=_blank>little impact on neutralization by moclonal antibodies</a>;
                            litte impact on neautralization by polyclonal antibodies
                            <a href="https://doi.org/10.1101/2021.01.25.428137" target=_blank>[1]</a>
                            <a href="https://doi.org/10.1101/2021.01.27.428516" target=_blank>[2]</a>
                        </td>
                    </tr>
                    <tr><!-- B.1.351 -->
                        <td><a href="/view/VariantLineage/#view_tab=lineage&loc=B.1.351">B.1.351</a></td>
                        <td><a href="https://cov-lineages.org/global_report_B.1.351.html" target=_blank>B.1.351</a></td>
                        <td>20H(Beta, V2)</td>
                        <td>Beta</td>
                        <td>VOC-20DEC02, South African variant</td>
                        <td>May 2020</td>
                        <td>South Africa</td>
                        <td>
                            <a href="https://www.viprbrc.org/brc/viprStrainDetails.spg?ncbiAccession=MW598408&decorator=corona_ncov&context=1625156219083" target=_blank>SARS-CoV-2/human/GHA/nmimr-SARS-CoV-2-TRA- 143/2021</a>
                        </td>
                        <td>(L18F*)**, D80A, D215G, L242-, A243-, L244-, (R246I*), K417N**, E484K**, N501Y**, D614G**, A701V</td>
                        <td>
                            Increased transmissibility (Pearson CAB, Russell TW, Davies NG, et al. Estimates of severity and transmissibility of novel South Africa SARS-CoV-2 variant 501Y.V2);
                            E484K appears to result in loss of serum antibody neutralization;
                            K417 is also found in RBD and may contribute to loss of serum antibody neutralization
                        </td>
                    </tr>
                    <tr><!-- B.1.617.2 -->
                        <td><a href="/view/VariantLineage/#view_tab=lineage&loc=B.1.617.2">B.1.617.2</a></td>
                        <td>B.1.617.2</td>
                        <td>21A(Delta)</td>
                        <td>Delta</td>
                        <td>B.1.617, VOC-21APR02</td>
                        <td>October 2020</td>
                        <td>India</td>
                        <td>
                            <a href="https://www.viprbrc.org/brc/viprStrainDetails.spg?ncbiAccession=MZ184193&decorator=corona_ncov&context=1625157326240" target=_blank>SARS-CoV-2/human/USA/IL-CDC-ASC210035446/2021</a>
                        </td>
                        <td>T19R, L452R, T478K, D614G, P681R,  D950N</td>
                        <td>Predominantly India lineage with several spike mutations; may have decreased Ab neutralization. </td>
                    </tr>
                    <tr><!-- AY.1 -->
                        <td><a href="/view/VariantLineage/#view_tab=lineage&loc=AY.1">AY.1</a></td>
                        <td>AY.1</td>
                        <td>21A(Delta)</td>
                        <td>Delta</td>
                        <td>B.1.617.2</td>
                        <td>April 2021</td>
                        <td>Multiple Countries</td>
                        <td>
                            <a href="https://www.ncbi.nlm.nih.gov/nuccore/MZ315637" target=_blank>SARS-CoV-2/human/USA/CA-CDC-STM-000072456/2021</a>
                        </td>
                        <td>T19R, W258L, K417N, L452R, T478K, D614G, P681R, D950N</td>
                        <td>Increased transmissibility; may have reduced neutralization by some monoclonal & polyclonal antibodies</td>
                    </tr>
                    <tr><!-- AY.2 -->
                        <td><a href="/view/VariantLineage/#view_tab=lineage&loc=AY.2">AY.2</a></td>
                        <td>AY.2</td>
                        <td>21A(Delta)</td>
                        <td>Delta</td>
                        <td>B.1.617.2</td>
                        <td>March 2021</td>
                        <td>USA</td>
                        <td>
                            <a href="https://www.ncbi.nlm.nih.gov/nuccore/MZ436591" target=_blank>SARS-CoV-2/human/USA/LSUH000677E2S1/2021</a>
                        </td>
                        <td>T19R, V70F, F157-, R158-, A222V, K417N, L452R, T478K, D614G, P681R, D950N</td>
                        <td>Increased transmissibility; may have reduced neutralization by some monoclonal & polyclonal antibodies</td>
                    </tr>
                    <tr><!-- AY.3 -->
                        <td><a href="/view/VariantLineage/#view_tab=lineage&loc=AY.2">AY.3</a></td>
                        <td>AY.3</td>
                        <td>21A(Delta)</td>
                        <td>Delta</td>
                        <td>B.1.617.2.3</td>
                        <td>April 2021</td>
                        <td>USA</td>
                        <td>
                            <a href="https://www.viprbrc.org/brc/viprStrainDetails.spg?ncbiAccession=MZ358404&decorator=corona&context=1628092432515" target=_blank>SARS-CoV-2/human/USA/OK-CDC-2-4451083/2021</a>
                        </td>
                        <td>T19R, E156G, F157-, R158-, L452R, T478K, D614G, P681R, D950N</td>
                        <td>Increased transmissibility; may have reduced neutralization by some monoclonal & polyclonal antibodies</td>
                    </tr>
                    <tr><!-- AY.3.1 -->
                        <td><a href="/view/VariantLineage/#view_tab=lineage&loc=AY.2">AY.3.1</a></td>
                        <td>AY.3.1</td>
                        <td>21A(Delta)</td>
                        <td>Delta</td>
                        <td>B.1.617.2.3.1</td>
                        <td>May 2021</td>
                        <td>USA</td>
                        <td>
                            <a href="https://www.viprbrc.org/brc/viprStrainDetails.spg?ncbiAccession=MZ505747&decorator=corona&context=1628092001989" target=_blank>SARS-CoV-2/human/USA/LA-BIE-LSUH000936/2021</a>
                        </td>
                        <td>T19R, V70F, F157-, R158-, A222V, K417N, L452R, T478K, D614G, P681R, D950N</td>
                        <td>Increased transmissibility; may have reduced neutralization by some monoclonal & polyclonal antibodies</td>
                    </tr>
                    <tr><!-- P.1 -->
                        <td><a href="/view/VariantLineage/#view_tab=lineage&loc=P.1">P.1</a></td>
                        <td><a href="https://cov-lineages.org/lineages/lineage_B.1.1.28.html" target=_blank>P.1</a></td>
                        <td>20J(Gamma, V3)</td>
                        <td>Gamma</td>
                        <td>20J/501Y.V3, VOC-20JAN02, B.1.1.248, Brazilian variant</td>
                        <td>November 2020</td>
                        <td>Brazil</td>
                        <td>
                            <a href="https://www.viprbrc.org/brc/viprStrainDetails.spg?ncbiAccession=MW642248&decorator=corona_ncov&context=1625158146181" target=_blank>SARS-CoV-2/human/ITA/ABR-IZSGC-TE30939/2021</a>
                        </td>
                        <td>L18F**, T20N, P26S, D138Y, R190S, K417T**, E484K**, N501Y**, D614G**, H655Y, T1027I, V1176F</td>
                        <td>Increased transmissibility; E484K appears to result in loss of serum antibody neutralization; K417 is also found in RBD and may contribute to loss of serum antibody neutralization</td>
                    </tr>
                </tbody>
            </table>
            * denotes mutations found in at least >25% variants, but not in all sequences</li>
            <br> ** denotes mutations found in more than one VoC indicating possible positive selection, shared ancestry and/or convergent evolution
        </div>
        <br/>
        <div class="section far2x">
            <h3 class="close2x section-title"><span class="wrap">Lineages of Interest</span></h3>
            <table class="p3basic striped">
                <thead>
                    <tr>
                        <th>LoI name</th>
                        <th>PANGO lineage</th>
                        <th>NextStrain lineage</th>
                        <th>WHO name</th>
                        <th>Other synonyms</th>
                        <th>Emergence date</th>
                        <th>Emergence location</th>
                        <th>Representative strain</th>
                        <th>AA substitutions in spike protein</th>
                        <th>Impact</th>
                    </tr>
                </thead>
                <tbody>
                    <tr><!-- B.1.427 -->
                        <td><a href="/view/VariantLineage/#view_tab=lineage&loc=B.1.427">B.1.427</a></td>
                        <td><a href="https://cov-lineages.org/lineages/lineage_B.1.427.html" target=_blank>B.1.427</a></td>
                        <td>21C(Epsilon)</td>
                        <td>Epsilon</td>
                        <td>20C/S:452R, CAL.20C </td>
                        <td>September 2020</td>
                        <td>Southern California, USA</td>
                        <td>
                            <a href="https://www.viprbrc.org/brc/viprStrainDetails.spg?ncbiAccession=MW795899&decorator=corona_ncov&context=1625158364610" target=_blank>SARS-CoV-2/human/USA/UT-UPHL-2103140561/2021</a>
                        </td>
                        <td>S13I, W152C,  L452R, D614G**</td>
                        <td>
                            <a href="https://doi.org/10.1101/2021.03.07.21252647" target=_blank>increased transmissibility</a>;
                            deacreased neutralization by some monoclonal antibodies;
                            <a href="https://doi.org/10.1101/2021.03.07.21252647" target=_blank>decreased neutralization by polyclonal anibodies </a>
                        </td>
                    </tr>
                    <tr><!-- B.1.429 -->
                        <td><a href="/view/VariantLineage/#view_tab=lineage&loc=B.1.429">B.1.429</a></td>
                        <td><a href="https://cov-lineages.org/lineages/lineage_B.1.429.html" target=_blank>B.1.429</a></td>
                        <td>21C(Epsilon)</td>
                        <th>Epsilon</th>
                        <td>20C/S:452R, CAL.20C </td>
                        <td>July 2020</td>
                        <td>Southern California, USA</td>
                        <td>
                            <a href="https://www.viprbrc.org/brc/viprStrainDetails.spg?ncbiAccession=MW907092&decorator=corona_ncov&context=1625158521949" target=_blank>SARS-CoV-2/human/USA/OH-UHTL-431/2021</a>
                        </td>
                        <td>S13I, W152C, L452R, D614G**</td>
                        <td>
                            <a href="https://doi.org/10.1101/2021.03.07.21252647" target=_blank>increased transmissibility</a>;
                            deacreased neutralization by some monoclonal antibodies;
                            <a href="https://doi.org/10.1101/2021.03.07.21252647" target=_blank>decreased neutralization by polyclonal anibodies </a>
                        </td>
                    </tr>
                    <tr><!-- B.1.525 -->
                        <td><a href="/view/VariantLineage/#view_tab=lineage&loc=B.1.525">B.1.525</a></td>
                        <td>B.1.525</td>
                        <td>21D(Eta)</td>
                        <td>Eta</td>
                        <td>VUI-21FEB03, 20A/S:484K</td>
                        <td>December 2020/td>
                        <td>Multiple</td>
                        <td>
                            <a href="https://www.viprbrc.org/brc/viprStrainDetails.spg?ncbiAccession=MW941945&decorator=corona_ncov&context=1625158781590" target=_blank>SARS-CoV-2/human/USA/GA-CDC-STM-000019151/2021</a>
                        </td>
                        <td>Q52R, E484K, D614G, Q677H, F888L</td>
                        <td>
                            Potential decreased neutralization by monoclonal and polyclonal antibodies.
                            International lineage with E484K, del69-70 among other defining mutations.
                        </td>
                    </tr>
                    <tr><!-- B.1.526 -->
                        <td><a href="/view/VariantLineage/#view_tab=lineage&loc=B.1.526">B.1.526</a></td>
                        <td>B.1.526</td>
                        <td>21F(Iota)</td>
                        <td>Iota</td>
                        <td>20C/S:484K, NY variant</td>
                        <td>November 2020</td>
                        <td>USA</td>
                        <td>
                            <a href="https://www.viprbrc.org/brc/viprStrainDetails.spg?ncbiAccession=MW943279&decorator=corona_ncov&context=1625158921723" target=_blank>SARS-CoV-2/human/USA/CT-CDC-STM-000025966/2021</a>
                        </td>
                        <td>L5F, T95I, D253G, E484K*, D614G, A701V</td>
                        <td>
                            Minimal decrease in neutralization by monoclonal and polyclonal antibodies
                            <a href="https://www.biorxiv.org/content/10.1101/2021.03.24.436620v1" target=_blank>[1]</a>
                        </td>
                    </tr>
                    <tr><!-- B.1.617.1 -->
                        <td><a href="/view/VariantLineage/#view_tab=lineage&loc=B.1.617.1">B.1.617.1</a></td>
                        <td>B.1.617.1</td>
                        <td>21B(Kappa)</td>
                        <td>Kappa</td>
                        <td>20A/S:154K, B.1.617, VUI-21APR01</td>
                        <td>December 2020</td>
                        <td>India</td>
                        <td>
                            <a href="https://www.viprbrc.org/brc/viprStrainDetails.spg?ncbiAccession=MW943960&decorator=corona_ncov&context=1625438339248" target=_blank>SARS-CoV-2/human/USA/FL-CDC-STM-000028344/2021</a>
                        </td>
                        <td>E154K, L452R, E484Q, D614G, P681R, Q1071H</td>
                        <td>Predominantly India lineage with 484Q; may have decreased Ab neutralization.</td>
                    </tr>
                    <tr><!-- B.1.617.3 -->
                        <td><a href="/view/VariantLineage/#view_tab=lineage&loc=B.1.617.3">B.1.617.3</a></td>
                        <td>B.1.617.3</td>
                        <td>20A</td>
                        <td>-</td>
                        <td>B.1.617</td>
                        <td>October 2020</td>
                        <td>India</td>
                        <td>
                            <a href="https://www.ncbi.nlm.nih.gov/nuccore/MZ359842" target=_blank>SARS-CoV-2/human/IND/GBRC709/2021</a>
                        </td>
                        <td>T19R, L452R, E484Q, D614G, P681R</td>
                        <td>Predominantly India lineage with 484Q</td>
                    </tr>
                </tbody>
            </table>
            * denotes mutations found in at least >25% variants, but not in all sequences</li>
            <br> ** denotes mutations found in more than one VoC indicating possible positive selection, shared ancestry and/or convergent evolution
        </div>
    </div>

    <div class="column-opt">
        <br/>
        <div class="section far2x">
            <h3 class="close2x section-title"><span class="wrap">Acknowledgements</span></h3>
            <p>
                We gratefully acknowledge the authors, originating and submitting laboratories that have shared their SARS-CoV-2 genomic data
                via <a href="https://www.ncbi.nlm.nih.gov/sars-cov-2/" target=_blank>GenBank and SRA</a> and <a href="https://www.cogconsortium.uk/" target=_blank>COG-UK</a>, which is used to build this system.
            </p>
        </div>
        <div class="section">
            <h3 class="close2x section-title"><span class="wrap">Recent PubMed Articles</span></h3>
            <div data-dojo-attach-point="pubmedSummaryNode">
                Loading...
            </div>
        </div>
    </div>
  </div>
